Osteoclast Inhibition and Bone Formation

Early Phase 1CompletedNCT02554695

Mayo Clinic81 enrolled

Overview

This protocol addresses: 1) How gene expression changes in bone cells are affected by aging? 2) Is aging associated with decreased signaling between bone cells? 3) How does treatment with the osteoporosis medication denosumab affect bone cell signaling?

This protocol collectively addresses the following goals: 1) What are the changes in gene expression in osteoblasts and osteocytes that lead to impaired bone formation with aging; 2) Since recent work from the investigators' group has demonstrated that osteoclasts produce a number of growth factors and cytokines (coupling factors) that enhance osteoblast proliferation and/or differentiation, is aging associated with reduced osteoclast coupling factor production; and 3) If osteoclasts are markedly reduced using the FDA-approved medication for osteoporosis, denosumab, how does that effect the quantity of coupling factors in the bone microenvironment and the target genes of these coupling factors in osteoblasts?

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

QUADRUPLE

Enrollment

Conditions

Bone Loss Aging

Interventions

placeboDRUG

subcutaneous saline injection

denosumabDRUG

single subcutaneous injection of denosumab 60 mg

Eligibility

Sex: FEMALEMin age: 25 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

* Inclusion Criteria: * normal premenopausal women aged 25-40 years * normal postmenopausal women aged 60-80 years * at least 5 yrs since their last menses * follicle stimulating hormone (FSH) \> 20 IU/L * Exclusion Criteria: * Abnormality in any of the screening laboratory studies * Presence of significant liver or renal disease * Malignancy (including myeloma) * Malabsorption * Diabetes * Hypoparathyroidism * Hyperparathyroidism * Acromegaly * Cushing's syndrome * Hypopituitarism * Severe chronic obstructive pulmonary disease * Undergoing treatment with any medications that affect bone turnover, including the following: * adrenocorticosteroids (\> 3 months at any time or \> 10 days within the previous yr) * anticonvulsant therapy (within the previous year) * pharmacological doses of thyroid hormone (causing decline of thyroid stimulating hormone below normal) * calcium supplementation of \> 1200 mg/d (within the preceding 3 months) * bisphosphonates (within the past 3 yrs) * denosumab * estrogen (E) therapy within the past year * treatment with a selective E receptor modulator within the past year * teriparatide within the past yr * Clinical history of osteoporotic fracture (vertebral, hip, or distal forearm) * Recent (within the past 6 months) fracture * Serum 25-hydroxyvitamin D levels of \< 20 ng/ml

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Outcomes

Primary Outcomes

Gene expression changes in bone cells

Ratio of selected genes as expressed between each of the 3 arms (i.e. relative runx2 gene expression levels in each arm).

Time frame: 3 months

Secondary Outcomes

Osteoclast-osteoblast coupling factor changes

Ratio of selected genes as expressed between each of the 3 arms (i.e. relative runx2 gene expression levels in each arm).

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.